TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16037146

Group type: EXPERIMENTAL
Intervention: Group 1 (0.6% end‐tidal isoflurane plus fentanyl)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 2 (1.2% end‐tidal isoflurane plus fentanyl)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 3 (1.8% end‐tidal isoflurane plus fentanyl)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group 4 (only isoflurane)
Number of subjects: 80
Study: 12453969

Group type: EXPERIMENTAL
Intervention: Iron depletion (three extractions of 500 ml blood at 2-week intervals; group 1A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Observation (group 1B)
Number of subjects: 28
Study: 10075342

Group type: EXPERIMENTAL
Intervention: Mixed MCT-LCT emulsion (n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: LCT emulsion (n = 7)
Number of subjects: 14
Study: 7555551

Group type: EXPERIMENTAL
Intervention: Acarbose (50 to 300 mg three times daily)
Number of subjects: 0
Study: 2178677

Group type: EXPERIMENTAL
Intervention: Bilamellar tarsal rotation
Number of subjects: 165

Group type: COMPARATOR
Intervention: Eversion splinting
Number of subjects: 165

Group type: COMPARATOR
Intervention: Tarsal advance
Number of subjects: 165

Group type: COMPARATOR
Intervention: Tarsal grooving
Number of subjects: 165

Group type: COMPARATOR
Intervention: Tarsal advance and rotation
Number of subjects: 165

Group type: COMPARATOR
Intervention: Tarsal advance (for lid closure defect)
Number of subjects: 165
Study: 7425398

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30394326

Group type: EXPERIMENTAL
Intervention: Dopaminergic therapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Exogenous dopamine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Patients with Parkinson's disease (PD)
Number of subjects: 37
Study: 29110690

Group type: EXPERIMENTAL
Intervention: Tissue-engineered cartilage constructed using biomimetic cartilage extracellular‐matrix‐oriented scaffolds combined with autologous chondrocytes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Arthroscopic debridement and microfracture surgery
Number of subjects: 100
Study: 25367310

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 26280726

Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy system (Group MED)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Anterior open approach (Group AOA)
Number of subjects: 32
Study: 22356848

Group type: EXPERIMENTAL
Intervention: Online network of OSH experts (ArboAntwoord)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Common information sources (control group)
Number of subjects: 218
Study: 19473853

Group type: EXPERIMENTAL
Intervention: Concomitant suture exclusion of the left atrial appendage
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no left atrial appendage exclusion)
Number of subjects: 43
Study: 17322179

Group type: EXPERIMENTAL
Intervention: Adherence-enhancing psychosocial interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacist-based interventions
Number of subjects: 0
Study: 15086235

Group type: EXPERIMENTAL
Intervention: Cooling helmet
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no cooling)
Number of subjects: 14
Study: 11800047

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Diphenhydramine (placebo control) infusion
Number of subjects: 19
Study: 9479922

Group type: EXPERIMENTAL
Intervention: Monitored chlorhexidine (CHX) gel treatment (3 x 5 min 1% CHX gel, monitored over 12 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional two-day CHX treatment (3 x 5 min 1% CHX gel on two consecutive days)
Number of subjects: 17
Study: 7977520

Group type: EXPERIMENTAL
Intervention: Nasal nafarelin, 400 micrograms/day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nasal nafarelin
Number of subjects: 75
Study: 2537095

Group type: EXPERIMENTAL
Intervention: enalapril (10-20 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 14
Study: 242030

Group type: EXPERIMENTAL
Intervention: Neoston (2 g, taken as two times two pills orally 2 and 5 hrs before tests)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (taken orally 2 and 5 hrs before tests)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neoston (2 g)
Number of subjects: 15
Study: 31218713

Group type: COMPARATOR
Intervention: Topical glucocorticoids (mometasone furoate, 100 µg in each nostril once daily) and saline irrigation (150 mL twice a day) for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation aerosol therapy composed of essential oils, saline, glucocorticoids, and antibiotics, once daily 5 times per week for 2 weeks
Number of subjects: 0
Study: 27668920

Group type: EXPERIMENTAL
Intervention: Over-the-head 2-thumb encircling technique (OTTT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional 2-finger technique (TFT)
Number of subjects: 50
Study: 25074688

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily for 24 weeks plus placebo injection every 2 weeks (Arm A)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily for 4 weeks, then 150 mg once daily up to Week 24 plus placebo injection every 2 weeks (Arm B)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily for 4 weeks, then 100 mg once daily up to Week 24 plus placebo injection every 2 weeks (Arm C)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks for 24 weeks plus oral placebo twice daily (Arm D)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Oral placebo twice daily for 6 weeks, plus placebo injection every 2 weeks, then a switch to arm A or B (Arm E)
Number of subjects: 279
Study: 23771400

Group type: EXPERIMENTAL
Intervention: Mechanical restraint
Number of subjects: 60

Group type: COMPARATOR
Intervention: Seclusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 21450019

Group type: EXPERIMENTAL
Intervention: Three versus six preoperative cycles of epirubicin/docetaxel + granulocyte colony‐stimulating factor
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: SNB after primary chemotherapy
Number of subjects: 292
Study: 18640474

Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg q6-8h
Number of subjects: 479

Group type: COMPARATOR
Intervention: Racemic albuterol 2.5 mg q1-4h
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Levalbuterol
Number of subjects: 479

Group type: COMPARATOR
Intervention: Racemic albuterol
Number of subjects: 479
Study: 16395181

Group type: EXPERIMENTAL
Intervention: Classification algorithm using physical therapists with varying levels of experience
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Individual examination items
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Centralization/peripheralization judgments with repeated or sustained extension or aberrant movement judgments
Number of subjects: 123
Study: 12737671

Group type: EXPERIMENTAL
Intervention: Combined low-dose oral contraceptives (specific types not detailed)
Number of subjects: 227
Study: 10709162

Group type: EXPERIMENTAL
Intervention: 201 mg fenofibrate + 40 mg pravastatin
Number of subjects: 23

Group type: COMPARATOR
Intervention: 201 mg fenofibrate alone
Number of subjects: 23

Group type: COMPARATOR
Intervention: 40 mg pravastatin alone
Number of subjects: 23
Study: 9360431

Group type: EXPERIMENTAL
Intervention: Single-dose ceftriaxone (2 g intravenous prior to surgery)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Multiple-dose cefuroxime (1.5 g intravenous prior to surgery and 750 mg intramuscular every 8 hours for 48 hours)
Number of subjects: 160
Study: 1570370

Group type: EXPERIMENTAL
Intervention: Clomethiazol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Clorazepate
Number of subjects: 41
Study: 3882679

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 51
Study: 31365624

Group type: EXPERIMENTAL
Intervention: Fructose (75g dissolved in 200 mL of mineral water)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Glucose (75g dissolved in 200 mL of mineral water)
Number of subjects: 16
Study: 29383375

Group type: EXPERIMENTAL
Intervention: First irrigation tested
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Other 3 irrigations
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 8 possible order combinations
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4 order conditions based on the first irrigation
Number of subjects: 15
Study: 26194449

Group type: EXPERIMENTAL
Intervention: Resistance training skill competency intervention
Number of subjects: 361

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 361
Study: 25453517

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formula (HMG)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lactulose (LG)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formula combined with lactulose (HMCLG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 80
Study: 21983842

Group type: EXPERIMENTAL
Intervention: Lichtenstein
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Desarda
Number of subjects: 101
Study: 20933321

Group type: EXPERIMENTAL
Intervention: PCA3 score ≥ 100
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCA3 score < 100
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined PCA3 ≥ 100
Number of subjects: 0
Study: 18226744

Group type: EXPERIMENTAL
Intervention: Randomized Trials (RCTs)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonrandomized Studies (NRSs)
Number of subjects: 48
Study: 15982122

Group type: EXPERIMENTAL
Intervention: Stationary running
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Walking to a target
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sidestepping at test
Number of subjects: 116

Group type: COMPARATOR
Intervention: Eyes open during treadmill adaptation
Number of subjects: 116
Study: 11871742

Group type: EXPERIMENTAL
Intervention: Low-fat content nutrient formula (ED group) with 3.4 g of fat per 2000-kcal dose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High amount of medium-chain triglycerides nutrient formula (TL group) with 55.6 g of fat per 2000-kcal dose
Number of subjects: 36
Study: 11092663

Group type: EXPERIMENTAL
Intervention: Levosimendan (10‐min intravenous bolus of 3, 6, 12, 24 or 36 microg/kg, followed by a 24‐h infusion of 0.05, 0.1, 0.2, 0.4 or 0.6 microg/kg/min)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151

Group type: COMPARATOR
Intervention: Dobutamine (open‐label infusion of 6 microg/kg/min)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 151
Study: 8810934

Group type: EXPERIMENTAL
Intervention: Dalteparin (200 IU kg‐1) given as a once‐daily subcutaneous injection
Number of subjects: 330

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) aPTT adjusted i.v. infusion for 6 to 10 days
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 330

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 330
Study: 1412723

Group type: EXPERIMENTAL
Intervention: OKT3 (5 mg/day) for the first 14 postoperative days
Number of subjects: 108

Group type: COMPARATOR
Intervention: CsA from the first postoperative day
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 108

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 108
Study: 4096744

Group type: EXPERIMENTAL
Intervention: Ticlopidine (750 mg/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nicotinate (control)
Number of subjects: 10
Study: 31243481

Group type: EXPERIMENTAL
Intervention: 150 mg L-DOPA
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 30022253

Group type: EXPERIMENTAL
Intervention: TBS assessment in men
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to BMI
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to age
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to diabetes
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to SSRI use
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to alcohol intake
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to history of fragility fractures
Number of subjects: 672
Study: 26584888

Group type: EXPERIMENTAL
Intervention: MultiGeneAngio (MGA) - a single intra-arterial infusion of transduced autologous venous smooth muscle cells expressing VEGF165 and endothelial cells expressing Ang-1 (Cohort 1: 1 × 10^7, Cohort 2: 2 × 10^7, Cohort 3: 5 × 10^7, Cohort 4: 7 × 10^7)
Number of subjects: 12
Study: 25342956

Group type: EXPERIMENTAL
Intervention: Philani Intervention Program (home visits by trained, paraprofessional community health workers)
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Control condition (comprehensive healthcare at community primary health care clinics)
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Both intervention and control conditions
Number of subjects: 1238
Study: 22434783

Group type: EXPERIMENTAL
Intervention: Twice-weekly, school-based, 10-min jumping regime
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Twice-weekly, school-based, 10-min jumping regime (boys)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Regular PE warm-up
Number of subjects: 99
Study: 20379190

Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg/day)
Number of subjects: 340
Study: 18807310

Group type: EXPERIMENTAL
Intervention: General medical journals
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Trials published in 2005
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Overall reporting of CONSORT items
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Ethical Issues reporting
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Funding and conflicts of interest declaration
Number of subjects: 151
Study: 15616239

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 1,000 mg/day t.i.d.
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 500 mg/day t.i.d.
Number of subjects: 1257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1257
Study: 12579174

Group type: EXPERIMENTAL
Intervention: Suction group (n = 80) received 4 L min(‐1) O(2) with nasal cannula and expired air was aspired with a Y‐piece suction system
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-suction group (n = 80) received 4 L min(‐1) O(2) with nasal cannula
Number of subjects: 160
Study: 10687256

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg daily for 2 years)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo (no pentoxifylline)
Number of subjects: 107
Study: 9590776

Group type: EXPERIMENTAL
Intervention: Sulperazon
Number of subjects: 67

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 67
Study: 29562597

Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 334

Group type: COMPARATOR
Intervention: Fruits and vegetables (F&V) diet
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Control diet
Number of subjects: 334
Study: 26508436

Group type: EXPERIMENTAL
Intervention: Pelvic packing (PACK)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Angioembolization (ANGIO)
Number of subjects: 56
Study: 25248910

Group type: EXPERIMENTAL
Intervention: Peer-led, community-based, stroke prevention self‐management group workshop (6 weeks, 1 session/week)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 600
Study: 22784842

Group type: EXPERIMENTAL
Intervention: Salsalate (3 g daily)
Number of subjects: 66
Study: 19404692

Group type: EXPERIMENTAL
Intervention: 10‐mg sustained‐release clotrimazole varnish
Number of subjects: 14

Group type: COMPARATOR
Intervention: 10‐mg clotrimazole oral troche
Number of subjects: 14
Study: 18225447

Group type: EXPERIMENTAL
Intervention: CB1 antagonists; specific dosage and duration not available
Number of subjects: 0
Study: 15795534

Group type: EXPERIMENTAL
Intervention: anti-activated factor X (anti-FXa) assay
Number of subjects: 46

Group type: COMPARATOR
Intervention: activated partial thromboplastin time (aPTT) assay
Number of subjects: 46
Study: 12038874

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short- and long-term inhaled bronchodilators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (cromolyn sodium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theophyllines (intravenous and oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Macrolide antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin, cyclosporine, leukotriene antagonists
Number of subjects: 0
Study: 9794853

Group type: EXPERIMENTAL
Intervention: Drug interventions
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Established quality of life instruments
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Developed measures
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Unclear methods
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Response rates
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Complete reporting
Number of subjects: 364
Study: 8904473

Group type: EXPERIMENTAL
Intervention: IVIG 800 mg/kg/day for 3 days plus phototherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Phototherapy only
Number of subjects: 40
Study: 2694046

Group type: EXPERIMENTAL
Intervention: Spectacle lenses with prism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without prism)
Number of subjects: 0
Study: 739228

Group type: EXPERIMENTAL
Intervention: Guthion-treated plot
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control plot
Number of subjects: 15
Study: 31046493

Group type: EXPERIMENTAL
Intervention: Medicinal plants used in the treatment of kidney stones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effective management options
Number of subjects: 0
Study: 28438147

Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy
Number of subjects: 501

Group type: COMPARATOR
Intervention: Treatment as usual (mostly cognitive-based therapy)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Patients with depression, anxiety, stress, and adjustment disorders
Number of subjects: 501

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 501
Study: 25555830

Group type: EXPERIMENTAL
Intervention: Individualized complementary medicine (CM group)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Usual care (usual care group)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Comparison between CM group and usual care group
Number of subjects: 275
Study: 24303433

Group type: EXPERIMENTAL
Intervention: 4ml of solution containing 1:200000 adrenaline and 2mg/kg tramadol injected in peritonsillar space (Group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 4ml of normal saline injected in peritonsillar space (Group B)
Number of subjects: 46
Study: 21716117

Group type: EXPERIMENTAL
Intervention: Prophylactic analgesia with sublingual tramadol Hcl (50 mg) and oral lorazepam (1 mg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Oral diazepam (5 mg) alone
Number of subjects: 113
Study: 19247187

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment with statin therapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment in patients with diabetes
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment in tobacco smokers
Number of subjects: 105
Study: 16490846

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Surgical excision
Number of subjects: 408
Study: 12766921

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 66
Study: 10694560

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PeCT) - fluorouracil, doxorubicin, and cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 0
Study: 9366939

Group type: EXPERIMENTAL
Intervention: Rolled gauze swabs
Number of subjects: 120

Group type: COMPARATOR
Intervention: Guedel airway
Number of subjects: 120
Study: 8251962

Group type: EXPERIMENTAL
Intervention: Rational statements
Number of subjects: 27

Group type: COMPARATOR
Intervention: Irrational statements
Number of subjects: 27
Study: 3005801

Group type: EXPERIMENTAL
Intervention: Cortisol administration after a midnight dose of metyrapone (30 mg/kg)
Number of subjects: 24
Study: 31870463

Group type: EXPERIMENTAL
Intervention: EMIQ® (2 mg aglycone equivalent)/kg body weight
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 28143667

Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with extra-virgin olive oil
Number of subjects: 870

Group type: COMPARATOR
Intervention: MedDiet supplemented with nuts
Number of subjects: 870

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 870

Group type: COMPARATOR
Intervention: Total and common olive oil consumption
Number of subjects: 870
Study: 27825327

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 207
Study: 24739452

Group type: EXPERIMENTAL
Intervention: Four-year, class-based curriculum intervention (22 classroom lessons)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Existing educational course regarding smoking
Number of subjects: 100
Study: 22269076

Group type: EXPERIMENTAL
Intervention: Self-administered stress management training (SSMT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual psychosocial care only
Number of subjects: 220